Novel Sequencing Based Diagnostics for Leukemia in Low Resource Settings

资源匮乏环境下基于测序的新型白血病诊断

基本信息

批准号：
10357301
负责人：
Thomas Blick Alexander
金额：
$ 21.81万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10357301
关键词：
Acute leukemia Affect Aneuploidy B-Cell Acute Lymphoblastic Leukemia Base Pairing Bioinformatics Biological Biological Assay Biology Cancer Center Cancer Diagnostics Capital Child Classification Clinical Clinical Management Clinical Oncology Clinical Research Collaborations Collection Computational algorithm Computing Methodologies Core-Binding Factor Country Cytogenetics DNA Sequence Alteration Data Deposition Development Diagnosis Diagnostic ETV6 gene Economics Ensure Environment FLT3 gene Flow Cytometry Fluorescent in Situ Hybridization Gene Expression Gene Expression Profile Gene Expression Profiling Genomics Genotype Goals Gold Immunohistochemistry Income Infrastructure International Investments Lymphoid Maintenance Malawi Malignant Childhood Neoplasm Malignant Neoplasms Methods Molecular Mutation Myeloid Leukemia North Carolina Oncology Pathologic Pathologist Pathology Patients Protocols documentation RNA RUNX1 gene Research Resource-limited setting Resources Risk Sampling Secure Selection for Treatments Site Specimen Survival Rate Systems Analysis Technology Training Transcript Universities Validation accurate diagnostics anticancer research base cancer care cancer diagnosis care delivery classification algorithm clinical diagnosis clinical sequencing clinically actionable cloud based cohort computational pipelines computerized data processing cost cost effective data management data submission diagnostic accuracy diagnostic strategy diagnostic technologies diagnostic tool effective therapy feasibility testing flexibility future implementation health economics implementation research implementation study improved infrastructure development innovation laboratory experience leukemia low and middle-income countries molecular pathology multidisciplinary nanopore novel pediatric acute leukemia peer pilot test precision medicine prospective response tissue processing tool transcriptome sequencing

项目摘要

Project Summary Most cases of cancer worldwide are diagnosed in low and middle income countries (LMIC), where access to diagnostic technologies is limited and survival rates are low. Diagnostic resources such as flow cytometry, cytogenetics, and molecular panels are inconsistently accessible or wholly unavailable. Specifically, pathologists and clinicians cannot reliably differentiate lymphoid- from myeloid leukemia, or stratify biologic risk, leading to inaccurate or incomplete diagnosis and inappropriate treatment selection, which contributes to lower survival rates. Through development of new technical and computational approaches and feasibility testing in Malawi, we propose to advance a novel cost-effective sequencing approach to improve comprehensive leukemia diagnosis in LMICs. Our approach, using unbiased Oxford Nanopore RNA sequencing, requires low capital and per specimen costs. We have performed nanopore RNA sequencing for gene expression analysis on 124 cases of acute leukemia, demonstrating high quality RNA transcripts across a range of input conditions. We developed a pipeline that classifies leukemia lineage and core genomic subtypes. We hypothesize that locally implemented genomic sequencing, with minimal capital investment and limited training, accompanied by appropriate computational algorithms, can overcome diagnostic deficiencies for acute leukemia. In the proposed project, we will demonstrate feasibility of unbiased nanopore RNA sequencing as a diagnostic tool for acute leukemia in a low resource setting through technical and computational implementation. In Malawi, we will train laboratory personal to generate nanopore RNA sequencing from sixty diagnostic acute leukemia specimens. We will develop protocols and regulatory approvals for deposition of data into a secure cloud base system for analysis, which will allow iterative improvement of classification algorithms through ongoing collection of long-read RNA sequencing data. In parallel, we will significantly expand our cohort of nanopore RNA sequencing cases at the University of North Carolina, improving computational algorithms to classify genomic subtypes based upon nanopore gene expression profiling, validated with pathologic diagnosis and short read (eg. Illumina) sequencing data. We will develop computational pipelines and explore sequencing depth required using unbiased nanopore RNA sequencing to directly identify genomic alterations, such as fusion transcripts, aneuploidy, and FLT3 internal tandem duplications, which could allow for precision medicine approaches. Throughout this research period, we will plan for a future implementation study with a multidisciplinary group of domestic and international collaborators with expertise in clinical oncology, pathology, genomics, health economics, and implementation. Our innovative diagnostic approach could provide lineage and genotype leukemia classification on a single cost-effective platform, leading to transformational change in the diagnostic accuracy and subsequent clinical management of patients with acute leukemia in LMICs.

项目概要全球大多数癌症病例都是在低收入和中等收入国家 (LMIC) 诊断的，这些国家可以获得诊断技术有限，存活率低。诊断资源，例如流式细胞仪、细胞遗传学和分子面板的访问不一致或完全不可用。具体而言，病理学家临床医生无法可靠地区分淋巴性白血病和骨髓性白血病，或对生物学风险进行分层，从而导致不准确或不完整的诊断以及不适当的治疗选择，导致生存率降低费率。通过在马拉维开发新技术和计算方法并进行可行性测试，我们建议推进一种新颖的、具有成本效益的测序方法来改善全面的白血病中低收入国家的诊断。我们的方法使用无偏见的 Oxford Nanopore RNA 测序，需要较低的资本和每个样本的成本。我们对124例急性白血病进行了纳米孔RNA测序进行基因表达分析，在一系列输入条件下展示高质量的 RNA 转录本。我们开发了一条管道对白血病谱系和核心基因组亚型进行分类。我们假设本地实施的基因组测序，以最少的资本投资和有限的培训，并伴随适当的计算算法，可以克服急性白血病的诊断缺陷。在拟议的项目中，我们将证明无偏纳米孔 RNA 测序作为诊断方法的可行性通过技术和计算实施在资源匮乏的情况下治疗急性白血病的工具。在马拉维，我们将培训实验室人员对 60 个诊断性急性白血病进行纳米孔 RNA 测序标本。我们将开发协议和监管批准，将数据存储到安全的云基础中分析系统，这将允许通过持续收集迭代改进分类算法长读RNA测序数据。与此同时，我们将显着扩大我们的纳米孔 RNA 队列北卡罗来纳大学的案例测序，改进了基因组分类的计算算法基于纳米孔基因表达谱的亚型，通过病理诊断和短读进行验证（例如 Illumina）测序数据。我们将开发计算管道并探索所需的测序深度使用无偏差的纳米孔 RNA 测序直接识别基因组改变，例如融合转录本，非整倍体和 FLT3 内部串联重复，这可以实现精准医学方法。在整个研究期间，我们将计划与多学科小组一起进行未来的实施研究拥有临床肿瘤学、病理学、基因组学、健康专业知识的国内外合作者经济和实施。我们的创新诊断方法可以提供谱系和基因型在一个具有成本效益的平台上进行白血病分类，导致诊断的变革中低收入国家急性白血病患者的准确性和后续临床管理。